Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic
https://doi.org/10.37489/0235-2990-2023-68-5-6-62-68
Abstract
The aim of the study is the assessment of the resistance levels dynamics in clinically significant infectious agents based on the consumption dynamics of antimicrobial drugs potentially effective against bacteria with acquired drug resistance in the hospitals of the Russian Federation during the COVID-19 pandemic (2020–2022) in comparison with 2019. Material and methods. Data on antimicrobial drugs used in the Russian Federation in the period 2019–2022 in the hospital segment were downloaded from the database provided by the analytical company AlphaRM. Calculation of the indicator «Frequency of prescribing antimicrobial drugs effective against multidrug-resistant pathogens per year» in each year of observation was performed. Results. During the COVID-19 pandemic, an almost twofold increase was registered in the frequency of prescribing antimicrobial drugs potentially effective against resistant strains of both Gram-negative and Gram-positive pathogens in the hospital segment: from 1.2 in 2019 to 2% in 2021; with a subsequent decrease to 1.92% in 2022 for antimicrobial drugs effective against Gram-negative pathogens; from 0.47 in 2019 to 1.17% in 2022 for antimicrobial drugs potentially effective against Gram-positive pathogens. Conclusions. Due to the fact that the appointment of antimicrobial drugs, potentially effective against resistant strains of Gram-positive and Gram-negative pathogens, is carried out not only in cases of confirmed bacterial infections, but also empirically, and taking into account the nosocomial nature of secondary bacterial infections, further epidemiological and pharmacoepidemiological studies are required to assess the contribution of excessive consumption of antimicrobial drugs in the escalation of the problem of bacterial resistance.
About the Authors
Y. M. Gomon
Pavlov First Saint Petersburg State Medical University (Pavlov University); Hospital of St. George the Great Martyr
Russian Federation
Russian Federation
D. Sc. in Medicine, Professor of the Department of Clinical Pharmacology and Evidence-based Medicine, Pavlov First Saint Petersburg State Medical University (Pavlov University) of the Ministry of Health of the Russian Federation; clinical pharmacologist at the Hospital of St. George the Great Martyr
A. A. Kolbin
Pavlov First Saint Petersburg State Medical University (Pavlov University); St Petersburg State University
Russian Federation
Russian Federation
D. Sc. in Medicine, Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, Pavlov First Saint Petersburg State Medical University (Pavlov University) of the Ministry of Health of the Russian Federation; Professor of the Department of Pharmacology, Faculty of Medicine, St. Petersburg State University
D. S. Budanov
Pavlov First Saint Petersburg State Medical University (Pavlov University); Hospital of St. George the Great Martyr
Russian Federation
Russian Federation
Doctor of the city center of innovative medical technologies, Pavlov First Saint Petersburg State Medical University (Pavlov University) of the Ministry of Health of the Russian Federation; Hospital of St. George the Great Martyr
References
1. Rawson T.M., Moore L.S.P., Zhu N. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020; 71 (9): 2459–2468. doi: 10.1093/cid/ciaa530.
2. Langford B.J., So M., Raybardhan S. et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020; 26 (12): 1622–1629. doi: 10.1016/j.cmi.2020.07.016.
3. Karnoukh K.I., Lazareva N.B. Analiz potrebleniya antibakterial'nykh sredstv na fone pandemii COVID-19: uroven' statsionara. Meditsinskij Sovet. 2021; 16: 118–128. doi: https://doi.org/10.21518/2079-701X-2021-16-118-128. (in Russian)
4. Rasmussen L., Wettermark B., Steinke D., Pottegård A. Core concepts in pharmacoepidemiology: Measures of drug utilization based on individual-level drug dispensing data. Pharmacoepidemiol Drug Saf. 2022; 31 (10): 1015–1026. doi: 10.1002/pds.5490.
5. Metodicheskie rekomendatsii «Diagnostika i antimikrobnaya terapiya infektsij, vyzvannykh polirezistentnymi shtammami mikroorganizmov» (obnovlenie 2022 g.). https://antimicrob.net/wp-content/uploads/MR_ABT-dlya_razmeshheniya_na_sayte.pdf. (in Russian)
6. ATC/DDD Index 2023. https://www.whocc.no/atc_ddd_index/.
7. Guidelines for ATC classification and DDD assignment. 2023. https://www.whocc.no/filearchive/publications/2023_guidelines_web.pdf.
8. Zdravookhranenie v Rossii. 2021: Stat.sb./Rosstat. M.: 2021; 171. https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2021.pdf. (in Russian)
9. Wolff D., Nee S., Hickey N.S., Marschollek M. Risk factors for COVID-19 severity and fatality: a structured literature review. Infection. 2021; 49 (1): 15–28. doi: 10.1007/s15010-020-01509-1.
10. Hu J., Wang Y. The Clinical characteristics and risk factors of severe COVID-19. Gerontology. 2021; 67 (3): 255–266. doi: 10.1159/000513400.
11. Kouhpayeh H. Clinical features predicting COVID-19 mortality risk. Eur J Transl Myol. 2022; 32 (2): 10268. doi: 10.4081/ejtm.2022.10268.
12. Kuz'menkov A.Jyu., Vinogradova A.G., Trushin I.V., Ejdel'shtejn M.V., Avramenko A.A., Dekhnich A.V., Kozlov R.S. AMRmap — sistema monitoringa antibiotikorezistentnosti v Rossii. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2021; 23 (2): 198–204. doi: https://doi.org/10.36488/cmac.2021.2.198-204. (in Russian)
13. Avdeeva M.G., Kulbuzheva M.I., Zotov S.V., Zhuravleva E.V., Yatsukova A.V. Mikrobnyj pejzazh u gospital'nykh bol'nykh s novoj koronavirusnoj infektsiej COVID-19, sravnitel'naya antibiotikorezistentnost' s «dokovidnym» periodom: prospektivnoe issledovanie. Kubanskij nauchnyj meditsinskij vestnik. 2021; 28 (5): 14–28. https://doi.org/10.25207/1608-6228-202128-5-14-28. (in Russian)
14. Strelkova D.A., Rachina S.A., Kuleshov V.G., s soavt. Mikrobiologicheskij monitoring patsientov s COVID-19 v ORIT: prospektivnoe nabljyudatel'noe issledovanie Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2022; 24 (3): 274–282. (in Russian)
15. Fukushige M., Ngo N.H., Lukmanto D., Fukuda S., Ohneda O. Effect of the COVID-19 pandemic on antibiotic consumption: A systematic review comparing 2019 and 2020 data. Front Public Health. 2022; 10: 946077. doi: 10.3389/fpubh.2022.946077.
16. Jeon K., Jeong S., Lee N., Park M.J., Song W., Kim H.S., Kim H.S., Kim J.S. Impact of COVID-19 on antimicrobial consumption and spread of multidrug-resistance in bacterial infections. Antibiotics (Basel). 2022; 11 (4): 535. doi: 10.3390/antibiotics11040535.
17. Friedli O., Gasser M., Cusini A., Fulchini R., Vuichard-Gysin D., Halder Tobler R., Wassilew N., Plüss-Suard C., Kronenberg A. Impact of the COVID-19 Pandemic on Inpatient Antibiotic Consumption in Switzerland. Antibiotics (Basel). 2022; 11 (6): 792. doi: 10.3390/antibiotics11060792.
18. Zakharenkov I.A., Rachina S.A., Kozlov R.S., Bel'kova Jyu.A. Potreblenie sistemnykh antibiotikov v Rossii v 2017–2021 gg.: osnovnye tendentsii. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2022; 24 (3): 220–225. (in Russian)
19. Lucien M.A.B., Canarie M.F., Kilgore P.E. et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. Int J Infect Dis. 2021; 104: 250–254. doi: 10.1016/j.ijid.2020.12.087.
20. O'Toole R.F. The interface between COVID-19 and bacterial healthcareassociated infections. Clin Microbiol Infect. 2021; 27 (12): 1772–1776. doi: 10.1016/j.cmi.2021.06.001.
21. Orthopoulos G., Santone E., Izzo F., Tirabassi M., Pérez-Caraballo A.M., Corriveau N., Jabbour N. Increasing incidence of complicated appendicitis during COVID-19 pandemic. Am J Surg. 2021; 221 (5): 1056–1060. doi: 10.1016/j.amjsurg.2020.09.026.
22. Kariya A., Krutsri C., Singhatas P., Sumritpradit P., Thampongsa T., Lertsitthichai P., Phoprom N. Incidence of complicated appendicitis during the COVID-19 pandemic: A systematic review and meta-analysis. Int J Surg Open. 2022; 45: 100512. doi: 10.1016/j.ijso.2022.100512.
23. Kumar A., Karn E., Trivedi K. et al. Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis. PLoS One. 2022; 17 (9): e0272840. doi: 10.1371/journal.pone.0272840.
24. So W., Simon M.S., Choi J.J., Wang T.Z., Williams S.C., Chua J., Kubin C.J. Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels. Intern Emerg Med. 2022; 17 (5): 1405–1412. doi: 10.1007/s11739-022-02955-5.
25. Ng T.M., Ong S.W.X., Loo A.Y.X., Tan S.H., Tay H.L., Yap M.Y., Lye D.C., Lee T.H., Young B.E. Antibiotic therapy in the treatment of COVID-19 pneumonia: who and when? Antibiotics (Basel). 2022; 11 (2): 184. doi: 10.3390/antibiotics11020184.
Review
For citations:
Gomon Y.M., Kolbin A.A., Budanov D.S. Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic. Antibiot Khimioter = Antibiotics and Chemotherapy. 2023;68(5-6):62-68. (In Russ.) https://doi.org/10.37489/0235-2990-2023-68-5-6-62-68
Views:
394
Email this article 